zolucatetide (FOG-001)

About Parabilis Medicines

Parabilis Medicines is a private, preclinical/clinical-stage biotech developing a novel class of stabilized helical peptide therapeutics via its proprietary Helicon platform. This platform combines AI, simulation, and extensive non-canonical amino acid chemistry to create cell-permeable peptides that can inhibit challenging intracellular protein-protein interactions, target proteins for degradation, and deliver radioligands. The company's lead program, zolucatetide, has received FDA Orphan Drug Designation for desmoid tumors, validating its approach to targeting the elusive β-catenin:TCF interaction.

Therapeutic Areas

Other Desmoid Tumors Drugs